Thursday, July 16, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128

Committee Members Present:
Robyn Seely, Pharm.D.  Jameson Rice, Pharm.D.
Clinton Sheffield, MD  Keith Tolman, MD

Committee Members Excused:
Beth Johnson, R.Ph.  Ellie Brownstein, MD
Elizabeth Young, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:
Trevor Smith, CPhT  Heather Santacruz, RN
Merelynn Berrett, RN  Chad Hope, Pharm.D

University of Utah Drug Information Center Staff Present:
Melissa Archer, Pharm.D.

Other Individuals Present:
Laura Hill, Abbvie  Jim Graves, BMS
Chris Conner, BMS  Michele Puyear, Gilead
Michelle Bice, Gilead  Mindy Peterson, UofU
James McAdams, Orexo  Lisa Jenson, Gilead
Cody Ball, Select Health  Natalia Ruiz, UofU
Lovell Robinson, Abbvie  Keisa Lynch, UofU
Charissa Anne, J&J  Ralph Guattieri, Merck
Efrain, Alton, Merck  Brandon Milne, Abbvie

Meeting conducted by: Robyn Seely

1. **Review and Approval of April and May Minutes:** Jameson Rice made a motion to approve the minutes from April and May. Clinton Sheffield seconded the motion. Keith Tolman abstained as he was not a member of the committee at the time. All in favor.

2. **Housekeeping:**
   a. Robyn Seely reminded everyone to sign in. She asked the board to keep in mind a person to nominate for the committee chairperson at the next meeting.
   b. Robyn Seely said that Lisa Hunt submitted her resignation from Utah Medicaid. She will work on the Wyoming Board of Pharmacy. She expressed appreciation for the
hard work she had put in while managing the P&T committee and PDL process.
c. The committee welcomed Chad Hope, the new Utah Medicaid pharmacy director.

3. **Drug Utilization Review (DUR) Board update:** The DUR board reviewed androgen agents at the last meeting.

4. **Hepatitis C Combination Agents (Harvoni and Viekira)** – Melissa Archer presented a review of the Hepatitis C combination agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Other States Report** – Trevor Smith presented information from other States, with their Preferred Drug List listings for the Hepatitis C combination agent drug class.

6. **Public Comments:**
   a. Laura Hill (Viekira, Abbvie) – Laura responded to questions about side effects from drug interactions. She said that not all patients will have interactions, and that Abbvie provides training materials so prescribers can be aware of potential interactions and change current medications that may interact with something else while on the medication.
   b. Michelle Puyear (Harvoni, Gilead) – Michelle responded to questions about drug interactions and provided some information about the patient assistance program for those who lack do not qualify for coverage of the medication.
   c. Keisa Lynch (UofU provider) – She requested that the committee make both medications available as preferred agents, as they can be used to treat different genotypes or patients with kidney failure.

7. **Board Discussion:**
   a. Keith Tolman said that he believes the main problems with these drugs is not the cost directly, but who pays it. He said that since there is not a single payer system in the United States, it makes it difficult for one plan to pay for it when the patient may not be on the plan long term. He then said that the prison systems is having some of the most difficult time paying for this drug and providing treatment for Hepatitis C.
   b. Chad Hope said that the prison system does not receive federal matching funds like Medicaid programs do, so the State has to provide for the entire cost of treatment.
   c. Keith Tolman said that Havoni could be considered safer because of fewer side effects than Viekira. He said the products are equally effective.
   d. Robyn said that if monitored for drug interactions, which all providers should do with all medications, the products are equally safe.
   e. Clinton made a motion saying that both combination agents are equally safe and effective for inclusion on the PDL. Keith Tolman seconded the motion. All in favor.

8. **Agents to treat Angina:** Melissa Archer presented a review of the agents to treat angina. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
9. Public Comment – none

10. Board Discussion –
   a. Keith Tolman made a motion that the agents are equally safe and effective. Clinton Sheffield seconded the motion. All in favor.
   b. Jameson Rice made a motion to include one immediate release nitroglycerin product available as a preferred agent. Keith Tolman seconded the motion. All in favor.

11. Meeting Adjourned

12. Next meeting is scheduled for August 20, 2015. Antiretroviral, Protease Inhibitors will be discussed.

Minutes prepared by Trevor Smith
Recording available upon request, send email to medicaidpharmacy@utah.gov